Cargando…

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals

BACKGROUND: The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. METHODS: Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawana-Tachikawa, Ai, Llibre, Josep M., Bravo, Isabel, Escrig, Roser, Mothe, Beatriz, Puig, Jordi, Puertas, Maria C., Martinez-Picado, Javier, Blanco, Julia, Manzardo, Christian, Miro, Jose M., Iwamoto, Aikichi, Pozniak, Anton L., Gatell, Jose M., Clotet, Bonaventura, Brander, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903883/ https://www.ncbi.nlm.nih.gov/pubmed/24475275 http://dx.doi.org/10.1371/journal.pone.0087334

Ejemplares similares

Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals
por: Massanella, Marta, et al.
Publicado: (2014)

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)
por: Mothe, Beatriz, et al.
Publicado: (2019)

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial
por: Rosás-Umbert, Miriam, et al.
Publicado: (2020)

Corrigendum to ‘Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)’ EClinicalMedicine 11 (2019) 65–80
por: Mothe, Beatriz, et al.
Publicado: (2020)

Gut microbiome signatures linked to HIV-1 reservoir size and viremia control
por: Borgognone, Alessandra, et al.
Publicado: (2022)

Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs
por: Puertas, Maria C, et al.
Publicado: (2018)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
por: Ananworanich, Jintanat, et al.
Publicado: (2015)

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
por: Mothe, Beatriz, et al.
Publicado: (2020)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

The Genome-wide Methylation Profile of CD4(+) T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression
por: Moron-Lopez, Sara, et al.
Publicado: (2020)

Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
por: Rusconi, Stefano, et al.
Publicado: (2013)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART
por: Buzón, Maria J., et al.
Publicado: (2011)

Small steps forward for HIV vaccine development
por: Mothe, Beatriz, et al.
Publicado: (2020)

Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment
por: Shikuma, Cecilia M., et al.
Publicado: (2023)

HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design
por: Bayón-Gil, Ángel, et al.
Publicado: (2020)

Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination
por: Duran-Castells, Clara, et al.
Publicado: (2023)

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial
por: Lafeuillade, Alain, et al.
Publicado: (2014)

Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study
por: Francisci, Daniela, et al.
Publicado: (2019)

Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions
por: Llano, Anuska, et al.
Publicado: (2013)

Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction
por: Duran-Castells, Clara, et al.
Publicado: (2023)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Definition of the viral targets of protective HIV-1-specific T cell responses
por: Mothe, Beatriz, et al.
Publicado: (2011)

Virological, Immune and Host genetics Markers in the Control of HIV Infection
por: Mothe, Beatriz, et al.
Publicado: (2009)

Novel Approaches Towards a Functional Cure of HIV/AIDS
por: Bailon, Lucia, et al.
Publicado: (2020)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Correction to: Novel Approaches Towards a Functional Cure of HIV/AIDS
por: Bailon, Lucia, et al.
Publicado: (2020)

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial
por: van Lelyveld, Steven F. L., et al.
Publicado: (2015)

Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes
por: Sued, Omar, et al.
Publicado: (2015)

Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control
por: Oriol-Tordera, Bruna, et al.
Publicado: (2020)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Modelling HIV-1 2-LTR dynamics following raltegravir intensification
por: Luo, Rutao, et al.
Publicado: (2013)

Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain
por: Llibre, Josep M, et al.
Publicado: (2013)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia
por: Llibre, Josep M., et al.
Publicado: (2015)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B
por: Rosás-Umbert, Miriam, et al.
Publicado: (2017)

Enhancement of Antiviral CD8(+) T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2019)

The infectious synapse formed between mature dendritic cells and CD4(+) T cells is independent of the presence of the HIV-1 envelope glycoprotein
por: Rodriguez-Plata, Maria T, et al.
Publicado: (2013)

Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study
por: Krikke, Maaike, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_imemncpvucd7ve4gcthq11o22t